American Society for Transplantation and Cellular Therapy | Strategic Alliance Partners

Overall, the findings highlight the potential of bispecific antibodies as salvage therapy post anti-CD19 CAR T cell treatment and challenges associated with allogeneic hematopoietic cell transplantation consolidation after bispecific antibodies therapy in patients with relapsed/refractory B-cell lymphomas .

A recent study published in Nucleus discussed the utility of T-cell replete cord blood transplant in patients with high-risk pediatric acute myeloid leukemia and myelodysplastic syndrome.

A recent study published in Nucleus highlighted the impact of graft-vs-host disease prophylaxis on cytomegalovirus reactivation.

Notch signaling acute gastrointestinal graft-vs-host disease was determined in a study analyzing mice and nonhuman primates.

ISB 1342 has shown improved safety and efficacy for patients with relapsed/refractory multiple myeloma.

Results from the phase 3 COG ALL1331 trial found the use of blinatumomab for pediatric patients with B-cell acute lymphoblastic leukemia improved efficacy.

The difference in utilizing cytomegalovirus reactivation outcomes while on posttransplantation cyclophosphamide vs other graft-vs-hose disease agents has led to a better understanding in long-term disease and reinfection rates.

A recent study has found that novel graft-versus-leukemia has minor histocompatibility antigens and was all validated.

Pediatric patients with acute lymphoblastic leukemia and have KMT2A rearrangements were evaluated in a recent study published in the British Journal of Haematology.

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia.

A recently published article highlights the use of CD4-positive/CD8-positive double-positive T cells as a predictive marker for graft-versus-host disease.

A recent study found for patients with graft-versus-host disease, a relationship was observed between CD38 expression which reduced survival and had a higher transplant-related mortality.

Jun J. Yang, PhD, reviews the use of ex vivo drug sensitivity profiles and in vivo early treatment response for patients with acute lymphoblastic leukemia.

Recent research found that the disialoganglioside 2–directed bispecific trifunctional antibody has 2 binding sites which allows for a mitigated T-cell anti-tumor response.

Alex Kradhim reviews how graft-versus-host disease can be maintained by tissue resident TCF-1+ T cells.

Alison Gulbis, PharmD, BCOP, discusses her experience of being a woman in the bone marrow transplant and cellular therapy field.

Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.

Rahul Banerjee, MD, FACP, recounts the recent Tandem meeting by highlighting an interesting study involving cell phones and cell therapies.

Eleanor Mayfield, ELS, reviews the role of bispecific antibodies in hematologic malignancies.

Eleanor Mayfield, ELS, discusses FLT3-ITD minimal residual disease in acute myeloid leukemia.

Alex Kadhim investigates outcomes in infant patients who receive blood and marrow transplantation.

ASTCT recently published an article by Eleanor Mayfield, ELS, in their journal Nucleus discussing minimal residual disease negativity in patients with multiple myeloma.

ASTCT recently published an article in their journal Nucleus discussing extracorporeal photopheresis compared with acute graft-versus-host disease after receipt of hematopoietic stem cell transplant in children or young adults.

ASTCT recently published an article in their journal Nucleus detailing the use of mesenchymal stromal cells for the treatment of graft-versus-host disease

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.

Mary Horowitz, MD, MS, discusses efforts to increase diversity in clinical trials for blood and bone marrow transplant.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.